Guanfacine Tablet, Extended Release
Product Images NDC 60429-961

10 FDA label images from Golden State Medical Supply, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 60429-961). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

60429 960 01ol

60429 960 01ol
Label for Guanfacine Extended-Release Tablets 1 mg, available in a bottle of 100 tablets. The product is labeled with NDC 60429-960-01 and is distributed by Golden State Medical Supply, Inc. Storage instructions specify keeping at 20° to 25°C (68° to 77°F). The label includes a barcode and the statement 'Rx only.'*
FDA Label Image

60429 961 01

60429 961 01
Packaging label for Guanfacine Extended-Release Tablets, 2 mg strength, containing 100 tablets. The label includes the NDC 60429-961-01 and indicates it is for prescription use only (Rx only). The labeler is Golden State Medical Supply, Inc. Storage instructions specify controlled room temperature 20° to 25°C (68° to 77°F).*
FDA Label Image

60429 962 01ol

60429 962 01ol
Label for Guanfacine Extended-Release Tablets 3 mg by Golden State Medical Supply, Inc. The package contains 100 tablets in extended-release oral dosage form. The label includes the NDC 60429-962-01 and storage instructions at 20° to 25°C. It also notes that each tablet contains 3.42 mg guanfacine hydrochloride equivalent to 3 mg guanfacine and that the tablets are film-coated and light-resistant.*
FDA Label Image

60429 963 01ol

60429 963 01ol
Label for Guanfacine Extended-Release Tablets 4 mg by Golden State Medical Supply, Inc. The label shows a bottle of 100 extended-release tablets with NDC 60429-963-01 and specifies oral use. It includes storage instructions and a note to see the package insert for dosage information. The label also features a barcode and noting the product is Rx only.*
FDA Label Image

Figure-1.jpg (Figure 1)

Figure-1.jpg (Figure 1)
A line graph depicting guanfacine plasma concentration (ng/mL) over 24 hours for Guanfacine Extended-Release Tablets, 1 mg QD, and Tenex, 1 mg QD. The x-axis represents time in hours, and the y-axis shows plasma concentration. Guanfacine extended-release shows a gradual increase and sustained plasma level, while Tenex peaks higher initially and declines more rapidly.*
FDA Label Image

Figure-2.jpg (Figure 2)

Figure-2.jpg (Figure 2)
A pharmacokinetic chart illustrating fold changes with 90% confidence intervals in Cmax and AUC for Guanfacine Extended-Release when coadministered with various CYP3A4/5 inhibitors and inducers, and other drugs including ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate. The x-axis shows change relative to reference, spanning 0 to 5.*
FDA Label Image

Figure-3.jpg (Figure 3)

Figure-3.jpg (Figure 3)
A forest plot showing the pharmacokinetic parameters Cmax and AUC for Oral Methylphenidate and Lisdexamfetamine Dimesylate, with fold change and 90% confidence intervals compared to a reference value. The x-axis represents the change relative to reference from 0.0 to 2.0.*
FDA Label Image

Figure-4.jpg (Figure 4)

Figure-4.jpg (Figure 4)
A line graph depicting time to treatment failure (days) on the x-axis and the treatment failure rate (%) on the y-axis. It compares two groups: Placebo (solid line) and SPD003 (dashed line), showing differences in treatment failure rates over approximately 200 days.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
FDA Label Image

Molecular-structure.jpg (Molecular Structure)

Molecular-structure.jpg (Molecular Structure)
Chemical structure of the active ingredient guanfacine hydrochloride, showing a dichlorobenzene ring connected to an amide and guanidine group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.